S G C Kroeze1, C Fritz2, L Basler2, E Gkika3,4,5, T B Brunner6, A L Grosu3,4,5, M Guckenberger2. 1. Department of Radiation Oncology, University Hospital Zurich, Rämistrasse 100, 8091, Zürich, Switzerland. Stephanie.kroeze@usz.ch. 2. Department of Radiation Oncology, University Hospital Zurich, Rämistrasse 100, 8091, Zürich, Switzerland. 3. Department of Radiation Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 4. German Cancer Consortium (DKTK) Partner Site Freiburg, Freiburg, Germany. 5. German Cancer Research Center (DKFZ), Heidelberg, Germany. 6. Department of Radiation Oncology, University Hospital Magdeburg, Magdeburg, Germany.
Abstract
INTRODUCTION: Stereotactic body radiotherapy (SBRT) is increasingly used in metastasized patients receiving targeted/immunotherapy. Information on safety and effectivity of concurrent SBRT and targeted/immunotherapy remains limited, resulting in a lack of consensus on treatment strategies. This study aimed to investigate how SBRT-experienced centers in German-speaking countries combine both therapies. MATERIALS AND METHODS: Patterns-of-care of combined treatment with SBRT and targeted/immunotherapy were assessed in 27 radiation oncology centers (19 German, 1 Austrian and 7 Swiss centers). A survey was performed to analyze the details of SBRT, SBRT planning and combined modality treatment. Consensus was defined as ≥75% agreement among participants. RESULTS: Most participants (60%) were university centers. SBRT for oligometastases has been performed since the year 2008 (median, range 1997-2016), since then a median of 140 cases (5-1100) of SBRT have been performed. In all, 67% performed concurrent SBRT and targeted agents. BRAF inhibitors and VEGF/EGFR inhibitors (bevacizumab [90%], erlotinib [11%], sorafenib [19%], lapatinib [4%]) were considered a contraindication. Bevacizumab was never given simultaneously with SBRT; other agents were given concurrently in 7-52% of centers. A majority (59%) paused targeted agents 1 week before/after SBRT. Only 1 center reduced SBRT dose when combined with targeted agents. CONCLUSION: Although evidence for safety and efficacy of concurrent SBRT and targeted agents is limited, it is regularly performed outside of clinical trials. The survey showed consensus not to combine SBRT with antiangiogenic agents, especially bevacizumab. Furthermore, SBRT with concurrent BRAF inhibitors should be practiced with caution and BRAF inhibitors should be paused at least 1 week before SBRT.
INTRODUCTION: Stereotactic body radiotherapy (SBRT) is increasingly used in metastasized patients receiving targeted/immunotherapy. Information on safety and effectivity of concurrent SBRT and targeted/immunotherapy remains limited, resulting in a lack of consensus on treatment strategies. This study aimed to investigate how SBRT-experienced centers in German-speaking countries combine both therapies. MATERIALS AND METHODS: Patterns-of-care of combined treatment with SBRT and targeted/immunotherapy were assessed in 27 radiation oncology centers (19 German, 1 Austrian and 7 Swiss centers). A survey was performed to analyze the details of SBRT, SBRT planning and combined modality treatment. Consensus was defined as ≥75% agreement among participants. RESULTS: Most participants (60%) were university centers. SBRT for oligometastases has been performed since the year 2008 (median, range 1997-2016), since then a median of 140 cases (5-1100) of SBRT have been performed. In all, 67% performed concurrent SBRT and targeted agents. BRAF inhibitors and VEGF/EGFR inhibitors (bevacizumab [90%], erlotinib [11%], sorafenib [19%], lapatinib [4%]) were considered a contraindication. Bevacizumab was never given simultaneously with SBRT; other agents were given concurrently in 7-52% of centers. A majority (59%) paused targeted agents 1 week before/after SBRT. Only 1 center reduced SBRT dose when combined with targeted agents. CONCLUSION: Although evidence for safety and efficacy of concurrent SBRT and targeted agents is limited, it is regularly performed outside of clinical trials. The survey showed consensus not to combine SBRT with antiangiogenic agents, especially bevacizumab. Furthermore, SBRT with concurrent BRAF inhibitors should be practiced with caution and BRAF inhibitors should be paused at least 1 week before SBRT.
Authors: Ivan R Diamond; Robert C Grant; Brian M Feldman; Paul B Pencharz; Simon C Ling; Aideen M Moore; Paul W Wales Journal: J Clin Epidemiol Date: 2014-04 Impact factor: 6.437
Authors: Maria J Sambade; Eldon C Peters; Nancy E Thomas; William K Kaufmann; Randall J Kimple; Janiel M Shields Journal: Radiother Oncol Date: 2011-02-04 Impact factor: 6.280
Authors: Brandon M Barney; Svetomir N Markovic; Nadia N Laack; Robert C Miller; Jann N Sarkaria; O Kenneth Macdonald; Heather J Bauer; Kenneth R Olivier Journal: Int J Radiat Oncol Biol Phys Date: 2013-09-01 Impact factor: 7.038
Authors: Axel Bex; Eric Jonasch; Arjan W Griffioen; Laurie A Mans; Annemarie M A de Graaf; Patrycja Nowak-Sliwinska; Céline L M M de Hoog; Trees A M de Jong; Florry A Vyth-Dreese; Judy R van Beijnum Journal: Clin Cancer Res Date: 2012-05-09 Impact factor: 12.531
Authors: Jens Jakob; Tom Lesluyes; Anna Simeonova-Chergou; Frederik Wenz; Peter Hohenberger; Frederic Chibon; Sophie Le Guellec Journal: Strahlenther Onkol Date: 2019-11-15 Impact factor: 3.621
Authors: Evert S M van Aken; Yvette M van der Linden; Johannes V van Thienen; Adrianus J de Langen; Corrie A M Marijnen; Monique C de Jong Journal: Clin Transl Radiat Oncol Date: 2022-01-28
Authors: Marc D Piroth; David Krug; Petra Feyer; René Baumann; Stephanie Combs; Marciana-Nona Duma; Jürgen Dunst; Gerd Fastner; Rainer Fietkau; Matthias Guckenberger; Wulf Haase; Wolfgang Harms; Thomas Hehr; Felix Sedlmayer; Rainer Souchon; V Strnad; Wilfried Budach Journal: Strahlenther Onkol Date: 2022-05-08 Impact factor: 4.033